Plain-English translation of NCT06250504 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether offering young people aged 15–30 a choice of HIV prevention options works better than the current standard. The options include daily oral pills, injections called cabotegravir (APRETUDE), vaginal rings (DAPIRING), and emergency prevention kits. The study takes place in rural South Africa and combines these medication choices with peer support and reproductive health services at mobile clinics.
Many young people stop taking daily HIV prevention pills because they are inconvenient or forget doses. This trial wants to see if giving people a choice of longer-acting options—like injections that last months or vaginal rings—along with community support can help more people actually use HIV prevention and reduce new infections.
You likely qualify if…
You likely don't qualify if…
If you join, you'll visit a mobile community clinic where a nurse will discuss your HIV prevention options with you—daily pills, injections, vaginal rings, or emergency kits—and help you choose what works best for your life. A peer navigator (someone from your community trained to support young people) will help remind you about follow-up visits and answer your questions. You'll have regular check-ins to make sure the medication is working well for you and to monitor your health.
AI-generated summary from trial data · Aug 7, 2026 · Not medical advice
South Africa